Literature DB >> 17433920

Epidemiology and outcomes of status epilepticus in the elderly.

Alan R Towne1.   

Abstract

Status epilepticus (SE) is a serious condition of prolonged or repetitive seizures. The annual incidence (86/100,000) of SE in the elderly who are aged 60 and greater is almost twice that of the general population and is even higher in those who are 70 years and older. Either acute or remote symptomatic stroke causes approximately 60% of SE seen in the elderly. SE is associated with a high mortality in the elderly (38%), with a rate approaching 50% in patients older than 80 years of age. Etiology is a strong determinant of mortality in the elderly: mortality approaches 100% in patients with anoxia and 30% in patients with either metabolic disorders, hemorrhages, tumors, or systemic infections. Mortality is almost three times higher in SE associated with acute ischemic stroke than in stroke alone, indicating synergistic effects. Duration of SE is also a factor in mortality. Treatment should be initiated for any convulsive seizure that lasts at least 10 min or is repetitive. An electroencephalogram (EEG) should be promptly obtained so that a diagnosis can be made without delay. Because older patients have a greater likelihood of nondiagnostic findings on routine EEGs, prolonged EEG recordings and inpatient video-EEG monitoring significantly increase the rate of establishing a definitive diagnosis. Nonconvulsive status epilepticus in the elderly is especially difficult to diagnose and should be evaluated with an EEG. Treatment of SE is complicated by altered pharmacokinetics in the elderly. Initial treatments, usually the administration of an intravenous benzodiazepine, have overall success rates of 55% for overt convulsive SE and 14.9% for subtle SE. For refractory SE, little is gained by using additional standard drugs, and general anesthesia with continuous EEG monitoring is recommended.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17433920     DOI: 10.1016/S0074-7742(06)81007-X

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  25 in total

1.  Susceptibility to Soman Toxicity and Efficacy of LY293558 Against Soman-Induced Seizures and Neuropathology in 10-Month-Old Male Rats.

Authors:  James P Apland; Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; Eric M Prager; Cara H Olsen; Maria F M Braga
Journal:  Neurotox Res       Date:  2017-08-03       Impact factor: 3.911

2.  Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis.

Authors:  Jason McMullan; Comilla Sasson; Arthur Pancioli; Robert Silbergleit
Journal:  Acad Emerg Med       Date:  2010-06       Impact factor: 3.451

3.  Altered Expression of Intersectin1-L in Patients with Refractory Epilepsy and in Experimental Epileptic Rats.

Authors:  Xiaoyan Yang; Xin Xu; Yujiao Zhang; Shasha Wang; Minghui Li; Xuefeng Wang
Journal:  Cell Mol Neurobiol       Date:  2015-03-18       Impact factor: 5.046

4.  Age-Related Susceptibility to Epileptogenesis and Neuronal Loss in Male Fischer Rats Exposed to Soman and Treated With Medical Countermeasures.

Authors:  Brenda Marrero-Rosado; Franco Rossetti; Matthew W Rice; Mark C Moffett; Robyn B Lee; Michael F Stone; Lucille A Lumley
Journal:  Toxicol Sci       Date:  2018-07-01       Impact factor: 4.849

5.  Pathophysiological considerations of seizures, epilepsy, and status epilepticus in the elderly.

Authors:  Rebecca M Verellen; Jose E Cavazos
Journal:  Aging Dis       Date:  2011-08-30       Impact factor: 6.745

6.  The established status epilepticus trial 2013.

Authors:  Thomas Bleck; Hannah Cock; James Chamberlain; James Cloyd; Jason Connor; Jordan Elm; Nathan Fountain; Elizabeth Jones; Daniel Lowenstein; Shlomo Shinnar; Robert Silbergleit; David Treiman; Eugen Trinka; Jaideep Kapur
Journal:  Epilepsia       Date:  2013-09       Impact factor: 5.864

7.  Seizures and epilepsy in elderly patients of an urban area of Iran: clinical manifestation, differential diagnosis, etiology, and epilepsy subtypes.

Authors:  Sayed Shahaboddin Tabatabaei; Ahmad Delbari; Reza Salman-Roghani; Leili Shahgholi; Reza Fadayevatan; Naghmeh Mokhber; Johan Lokk
Journal:  Neurol Sci       Date:  2012-12-12       Impact factor: 3.307

8.  Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study.

Authors:  Raoul Sutter; Stephan Marsch; Stephan Rüegg
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

9.  The brain, seizures and epilepsy throughout life: understanding a moving target.

Authors:  Tallie Z Baram
Journal:  Epilepsy Curr       Date:  2012-07       Impact factor: 7.500

10.  Age-dependent mortality in the pilocarpine model of status epilepticus.

Authors:  Robert E Blair; Laxmikant S Deshpande; William H Holbert; Severn B Churn; Robert J DeLorenzo
Journal:  Neurosci Lett       Date:  2009-02-21       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.